Role of STAT3 in transformation and drug resistance in CML

Frontiers in Oncology

Volumn 2, Issue APR, 2012, Pages

  Nair, Rajesh R ^a   Tolentino, Joel H ^a   Hazlehurst, Lori A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Bone marrow microenvironment; Chronic myeloid leukemia; Drug resistance; STAT3; Transformation

Indexed keywords

ADAPHOSTIN; BCR ABL PROTEIN; BORTEZOMIB; DASATINIB; IMATINIB; JANUS KINASE; NILOTINIB; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN;

CELL ADHESION; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DNA METHYLATION; EMBRYONIC STEM CELL; HUMAN; MINIMAL RESIDUAL DISEASE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR MICROENVIRONMENT;

EID: 84885472809     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00030     Document Type: Review

References (137)

1. Aggarwal, B. B., Kunnumakkara, A. B., Harikumar, K. B., Gupta, S. R., Tharakan, S. T., Koca, C., Dey, S., and Sung, B. (2009). Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann. N. Y. Acad. Sci. 1171, 59-76.
2. Aichberger, K. J., Mayerhofer, M., Krauth, M. T., Skvara, H., Florian, S., Sonneck, K., Akgul, C., Derdak, S., Pickl, W. F., Wacheck, V., Selzer, E., Monia, B. P., Moriggl, R., Valent, P., and Sillaber, C. (2005). Identification of Mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and Mcl-1 antisense oligonucleotides. Blood 105, 3303-3311.
3. Akaishi, H., Takeda, K., Kaisho, T., Shineha, R., Satomi, S., Takeda, J., and Akira, S. (1998). Defective IL-2-mediated IL-2 receptor alpha chain expression in Stat3-deficient T lymphocytes. Int. Immunol. 10, 1747-1751.
4. Akira, S. (2000). Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 19, 2607-2611.
5. Akira, S., Nishio, Y., Inoue, M., Wang, X. J., Wei, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M., and Kishimoto, T. (1994). Molecular cloning of Aprf, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77, 63-71.
6. Allan, N. C., Richards, S. M., and Shepherd, P. C. (1995). UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345, 1392-1397.
7. Allen, J. C., Talab, F., Zuzel, M., Lin, K., and Slupsky, J. R. (2011). c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells. Blood 117, 2414-2422.
8. Amin, H. M., Hoshino, K., Yang, H., Lin, Q., Lai, R., and Garcia-Manero, G. (2007). Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia. J. Pathol. 212, 402-410.
9. Bewry, N. N., Nair, R. R., Emmons, M. F., Boulware, D., Pinilla-Ibarz, J., and Hazlehurst, L. A. (2008). Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol. Cancer Ther. 7, 3169-3175.
10. Bhattacharya, S., Ray, R. M., and Johnson, L. R. (2005). STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem. J. 392, 335-344.
11. Bild, A. H., Turkson, J., and Jove, R. (2002). Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J. 21, 3255-3263.
12. Bonifazi, F., DE Vivo, A., Rosti, G., Guilhot, F., Guilhot, J., Trabacchi, E., Hehlmann, R., Hochhaus, A., Shepherd, P. C., Steegmann, J. L., Kluin-Nelemans, H. C., Thaler, J., Simonsson, B., Louwagie, A., Reiffers, J., Mahon, F. X., Montefusco, E., Alimena, G., Hasford, J., Richards, S., Saglio, G., Testoni, N., Martinelli, G., Tura, S., and Baccarani, M. (2001). Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98, 3074-3081.
13. Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W., and Darnell, J. E. Jr. (1998). Stat3 activation is required for cellular transformation by v-Src. Mol. Cell Biol. 18, 2553-2558.
14. Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., and Darnell, J. E. Jr. (1999). Stat3 as an oncogene. Cell 98, 295-303.
15. Bruecher-Encke, B., Griffin, J. D., Neel, B. G., and Lorenz, U. (2001). Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. Leukemia 15, 1424-1432.
16. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, B. J., and Lydon, N. B. (1996). Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100-104.
17. Carlesso, N., Frank, D. A., and Griffin, J. D. (1996). Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med. 183, 811-820.
18. Carlesso, N., Griffin, J. D., and Druker, B. J. (1994). Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene 9, 149-156.
19. Chong, Z. Z., and Maiese, K. (2007). The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol. Histopathol. 22, 1251-1267.
20. Chou, W. C., Levy, D. E., and Lee, C. K. (2006). STAT3 positively regulates an early step in B-cell development. Blood 108, 3005-3011.
21. Chung, C. D., Liao, J., Liu, B., Rao, X., Jay, P., Berta, P., and Shuai, K. (1997). Specific inhibition of Stat3 signal transduction by PIAS3. Science 278, 1803-1805.
22. Chung, Y. J., Park, B. B., Kang, Y. J., Kim, T. M., Eaves, C. J., and Oh, I. H. (2006). Unique effects of Stat3 on the early phase of hematopoietic stem cell regeneration. Blood 108, 1208-1215.
23. Coppo, P., Dusanter-Fourt, I., Millot, G., Nogueira, M. M., Dugray, A., Bonnet, M. L., Mitjavila-Garcia, M. T., Le Pesteur, D., Guilhot, F., Vainchenker, W., Sainteny, F., and Turhan, A. G. (2003). Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene 22, 4102-4110.
24. Coppo, P., Dusanter-Fourt, I., Vainchenker, W., and Turhan, A. G. (2009). BCR-ABL induces opposite phenotypes in murine ES cells according to STAT3 activation levels. Cell. Signal. 21, 52-60.
25. Coppo, P., Flamant, S., De Mas, V., Jarrier, P., Guillier, M., Bonnet, M. L., Lacout, C., Guilhot, F., Vainchenker, W., and Turhan, A. G. (2006). BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br. J. Haematol. 134, 171-179.
26. Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., and Druker, B. J. (2011). Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396-409.
27. Croker, B. A., Kiu, H., and Nicholson, S. E. (2008). SOCS regulation of the JAK/STAT signalling pathway. Semin. Cell Dev. Biol. 19, 414-422.
28. Cuevas, P., Diaz-Gonzalez, D., Sanchez, I., Lozano, R. M., Gimenez-Gallego, G., and Dujovny, M. (2006). Dobesilate inhibits the activation of signal transducer and activator of transcription 3, and the expression of cyclin D1 and bcl-XL in glioma cells. Neurol. Res. 28, 127-130.
29. Daheron, L., Opitz, S. L., Zaehres, H., Lensch, M. W., Andrews, P. W., Itskovitz-Eldor, J., and Daley, G. Q. (2004). LIF/STAT3 signaling fails to maintain self-renewal of human embryonic stem cells. Stem Cells 22, 770-778.
30. Dai, Y., Rahmani, M., Pei, X. Y., Dent, P., and Grant, S. (2004). Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and-independent mechanisms. Blood 104, 509-518.
31. Daley, G. Q., and Baltimore, D. (1988). Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. U.S.A. 85, 9312-9316.
32. Damiano, J. S., Hazlehurst, L. A., and Dalton, W. S. (2001). Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 15, 1232-1239.
33. Darnell, J. E. Jr. (1997). STATs and gene regulation. Science 277, 1630-1635.
34. Dasmahapatra, G., Nguyen, T. K., Dent, P., and Grant, S. (2006). Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. Leuk. Res. 30, 1263-1272.
35. de Groot, R. P., Raaijmakers, J. A., Lammers, J. W., Jove, R., and Koenderman, L. (1999). STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 94, 1108-1112.
36. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566.
37. Drummond, M. W., Heaney, N., Kaeda, J., Nicolini, F. E., Clark, R. E., Wilson, G., Shepherd, P., Tighe, J., Mclintock, L., Hughes, T., and Holyoake, T. L. (2009). A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia 23, 1199-1201.
38. Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J. M., Yang-Yen, H. F., Karras, J., Jove, R., and Loughran, T. P. Jr. (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 107, 351-362.
39. Era, T., and Witte, O. N. (2000). Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc. Natl. Acad. Sci. U.S.A. 97, 1737-1742.
40. Ernst, M., Novak, U., Nicholson, S. E., Layton, J. E., and Dunn, A. R. (1999). The carboxyl-terminal domains of gp130-related cytokine receptors are necessary for suppressing embryonic stem cell differentiation. Involvement of STAT3. J. Biol. Chem. 274, 9729-9737.
41. Esposito, N., Colavita, I., Quintarelli, C., Sica, A. R., Peluso, A. L., Luciano, L., Picardi, M., Del Vecchio, L., Buonomo, T., Hughes, T. P., White, D., Radich, J. P., Russo, D., Branford, S., Saglio, G., Melo, J. V., Martinelli, R., Ruoppolo, M., Kalebic, T., Martinelli, G., and Pane, F. (2011). SHP1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood 118, 3634-3644.
42. Fang, B., Mai, L., Li, N., Song, Y., and Chunhua Zhao, R. (2011). Imatinib plus granulocyte colony-stimulating factor in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response while on imatinib. Case. Rep. Oncol. 4, 192-197.
43. Ferguson, L. R., Han, D. Y., Fraser, A. G., Huebner, C., Lam, W. J., Morgan, A. R., Duan, H., and Karunasinghe, N. (2010). Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat. Res. 690, 108-115.
44. Foo, J., Drummond, M. W., Clarkson, B., Holyoake, T., and Michor, F. (2009). Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput. Biol. 5, e1000503. doi:10.1371/journal.pcbi.1000503
45. Fornek, J. L., Tygrett, L. T., Waldschmidt, T. J., Poli, V., Rickert, R. C., and Kansas, G. S. (2006). Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells. Blood 107, 1085-1091.
46. Fukuchi, Y., Kizaki, M., Yamato, K., Kawamura, C., Umezawa, A., Hata, J., Nishihara, T., and Ikeda, Y. (2001). Mcl-1, an early-induction molecule, modulates activin A-induced apoptosis and differentiation of CML cells. Oncogene 20, 704-713.
47. Gishizky, M. L., Johnson-White, J., and Witte, O. N. (1993). Evaluating the effect of P210 BCR/ABL on growth of hematopoietic progenitor cells and its role in the pathogenesis of human chronic myelogenous leukemia. Semin. Hematol. 30, 6-8.
48. Gossen, M., and Bujard, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U.S.A. 89, 5547-5551.
49. Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., Yoder, S., Enkemann, S., Eschrich, S., Lee, J. H., Beam, C. A., Cheng, J., Minton, S., Muro-Cacho, C. A., and Jove, R. (2006). Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 12, 11-19.
50. Groner, B., Lucks, P., and Borghouts, C. (2008). The function of Stat3 in tumor cells and their microenvironment. Semin. Cell Dev. Biol. 19, 341-350.
51. Guillem, V., Amat, P., Cervantes, F., Alvarez-Larran, A., Cervera, J., Maffioli, M., Bellosillo, B., Collado, M., Marugan, I., Martinez-Ruiz, F., and Hernandez-Boluda, J. C. (2012). Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia. Leuk. Res. 36, 174-181.
52. Guo-Bao, W., Xiao-Qin, C., Qi-Rong, G., Jie, L., Gui-Nan, L., and Yue, L. (2010). Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line. Leuk. Lymphoma 51, 1090-1097.
53. Hankey, P. A. (2009). Regulation of hematopoietic cell development and function by Stat3. Front. Biosci. 14, 5273-5290.
54. Hantschel, O., Warsch, W., Eckelhart, E., Kaupe, I., Grebien, F., Wagner, K. U., Superti-Furga, G., and Sexl, V. (2012). BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat. Chem. Biol. 8, 285-293.
55. Harris, T. J., Grosso, J. F., Yen, H. R., Xin, H., Kortylewski, M., Albesiano, E., Hipkiss, E. L., Getnet, D., Goldberg, M. V., Maris, C. H., Housseau, F., Yu, H., Pardoll, D. M., and Drake, C. G. (2007). Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J. Immunol. 179, 4313-4317.
56. Heinrich, P. C., Behrmann, I., Haan, S., Hermanns, H. M., Muller-Newen, G., and Schaper, F. (2003). Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374, 1-20.
57. Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F., and Graeve, L. (1998). Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334(Pt 2), 297-314.
58. Herrington, J., Smit, L. S., Schwartz, J., and Carter-Su, C. (2000). The role of STAT proteins in growth hormone signaling. Oncogene 19, 2585-2597.
59. Herrmann, A., Vogt, M., Monnigmann, M., Clahsen, T., Sommer, U., Haan, S., Poli, V., Heinrich, P. C., and Muller-Newen, G. (2007). Nucleocytoplasmic shuttling of persistently activated STAT3. J. Cell Sci. 120, 3249-3261.
60. Hiwase, D. K., White, D. L., Powell, J. A., Saunders, V. A., Zrim, S. A., Frede, A. K., Guthridge, M. A., Lopez, A. F., D'Andrea, R. J., To, L. B., Melo, J. V., Kumar, S., and Hughes, T. P. (2010). Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia 24, 771-778.
61. Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., Goldman, J. M., Muller, M. C., Radich, J. P., Rudoltz, M., Mone, M., Gathmann, I., Hughes, T. P., and Larson, R. A. (2009). Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23, 1054-1061.
62. Hoelbl, A., Schuster, C., Kovacic, B., Zhu, B., Wickre, M., Hoelzl, M. A., Fajmann, S., Grebien, F., Warsch, W., Stengl, G., Hennighausen, L., Poli, V., Beug, H., Moriggl, R., and Sexl, V. (2010). Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol. Med. 2, 98-110.
63. Holyoake, T., Jiang, X., Eaves, C., and Eaves, A. (1999). Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94, 2056-2064.
64. Ihle, J. N. (2001). The stat family in cytokine signaling. Curr. Opin. Cell Biol. 13, 211-217.
65. Ilaria, R. L. Jr., and Van Etten, R. A. (1995). The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells. Blood 86, 3897-3904.
66. Ilaria, R. L. Jr., and Van Etten, R. A. (1996). P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271, 31704-31710.
67. Jabalameli, M. R. (2011). Role of STAT3 Locus in autoimmune diseases. Genes Immun. 12, 155 [author reply 156].
68. Jia, H. Y., Wu, J. X., Zhu, X. F., Chen, J. M., Yang, S. P., Yan, H. J., Tan, L., Zeng, Y. X., and Huang, W. (2009). ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells. Leuk. Res. 33, 1512-1519.
69. Johnson, F. M., Saigal, B., Tran, H., and Donato, N. J. (2007). Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin. Cancer Res. 13, 4233-4244.
70. Johnston, P. A., and Grandis, J. R. (2011). STAT3 signaling: anticancer strategies and challenges. Mol. Interv. 11, 18-26.
71. Jorgensen, H. G., Copland, M., Allan, E. K., Jiang, X., Eaves, A., Eaves, C., and Holyoake, T. L. (2006). Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin. Cancer Res. 12, 626-633.
72. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., Bochinski, K., Hochhaus, A., Griffin, J. D., Hoelzer, D., Albitar, M., Dugan, M., Cortes, J., Alland, L., and Ottmann, O. G. (2006). Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542-2551.
73. Kantarjian, H., Pasquini, R., Levy, V., Jootar, S., Holowiecki, J., Hamerschlak, N., Hughes, T., Bleickardt, E., Dejardin, D., Cortes, J., and Shah, N. P. (2009). Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 115, 4136-4147.
74. Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., Nakamae, H., Huguet, F., Boque, C., Chuah, C., Bleickardt, E., Bradley-Garelik, M. B., Zhu, C., Szatrowski, T., Shapiro, D., and Baccarani, M. (2010). Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362, 2260-2270.
75. Kantarjian, H. M., Hochhaus, A., Saglio, G., Souza, C. D., Flinn, I. W., Stenke, L., Goh, Y. T., Rosti, G., Nakamae, H., Gallagher, N. J., Hoenekopp, A., Blakesley, R. E., Larson, R. A., and Hughes, T. P. (2011). Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 12, 841-851.
76. Kato, Y., Iwama, A., Tadokoro, Y., Shimoda, K., Minoguchi, M., Akira, S., Tanaka, M., Miyajima, A., Kitamura, T., and Nakauchi, H. (2005). Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J. Exp. Med. 202, 169-179.
77. Konig, H., Holtz, M., Modi, H., Manley, P., Holyoake, T. L., Forman, S. J., and Bhatia, R. (2008). Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 22, 748-755.
78. Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., and Craig, R. W. (1993). MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl. Acad. Sci. U.S.A. 90, 3516-3520.
79. Kreil, S., Waghorn, K., Ernst, T., Chase, A., White, H., Hehlmann, R., Reiter, A., Hochhaus, A., and Cross, N. C. (2010). A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon alpha. Haematologica 95, 148-152.
80. Laouar, Y., Welte, T., Fu, X. Y., and Flavell, R. A. (2003). STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity 19, 903-912.
81. Lee, S. J., Lee, J. R., Hahn, H. S., Kim, Y. H., Ahn, J. H., Bae, C. D., Yang, J. M., and Hahn, M. J. (2007). PIAS1 interacts with the KRAB zinc finger protein, ZNF133, via zinc finger motifs and regulates its transcriptional activity. Exp. Mol. Med. 39, 450-457.
82. Levy, D. E., and Darnell, J. E. Jr. (2002). Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3, 651-662.
83. Litonjua, A. A., Tantisira, K. G., Lake, S., Lazarus, R., Richter, B. G., Gabriel, S., Silverman, E. S., and Weiss, S. T. (2005). Polymorphisms in signal transducer and activator of transcription 3 and lung function in asthma. Respir. Res. 6, 52.
84. Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A., Das, J., Doweyko, A. M., Fairchild, C., Hunt, J. T., Inigo, I., Johnston, K., Kamath, A., Kan, D., Klei, H., Marathe, P., Pang, S., Peterson, R., Pitt, S., Schieven, G. L., Schmidt, R. J., Tokarski, J., Wen, M. L., Wityak, J., and Borzilleri, R. M. (2004). Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661.
85. Lugo, T. G., Pendergast, A. M., Muller, A. J., and Witte, O. N. (1990). Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079-1082.
86. Lutticken, C., Wegenka, U. M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., Harpur, A. G., Wilks, A. F., Yasukawa, K., Taga, T., Kishimoto, T., Barbieri, G., Pellegrini, S., Sendtner, M., Heinrich, P. C., and Horn, F. (1994). Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 263, 89-92.
87. Ma, L. D., Zhou, M., Wen, S. H., Ni, C., Jiang, L. J., Fan, J., and Xia, L. (2010). Effects of STAT3 silencing on fate of chronic myelogenous leukemia K562 cells. Leuk. Lymphoma 51, 1326-1336.
88. Marrero, M. B., Schieffer, B., Paxton, W. G., Heerdt, L., Berk, B. C., Delafontaine, P., and Bernstein, K. E. (1995). Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 375, 247-250.
89. Mencalha, A. L., Du Rocher, B., Salles, D., Binato, R., and Abdelhay, E. (2010). LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. Cancer Chemother. Pharmacol. 65, 1039-1046.
90. Nair, R. R., Tolentino, J. H., Argilagos, R. F., Zhang, L., Pinilla-Ibarz, J., and Hazlehurst, L. A. (2011). Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. Leuk. Res. doi: 10.1016/j.leukres.2011.12.002. [Epub ahead of print].
91. Nakamura, Y., Yujiri, T., Nawata, R., Tagami, K., and Tanizawa, Y. (2005). MEK kinase 1 is essential for Bcr-Abl-induced STAT3 and self-renewal activity in embryonic stem cells. Oncogene 24, 7592-7598.
92. Nakano, T., Kodama, H., and Honjo, T. (1994). Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science 265, 1098-1101.
93. Neviani, P., Santhanam, R., Trotta, R., Notari, M., Blaser, B. W., Liu, S., Mao, H., Chang, J. S., Galietta, A., Uttam, A., Roy, D. C., Valtieri, M., Bruner-Klisovic, R., Caligiuri, M. A., Bloomfield, C. D., Marcucci, G., and Perrotti, D. (2005). The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8, 355-368.
94. Nieborowska-Skorska, M., Wasik, M. A., Slupianek, A., Salomoni, P., Kitamura, T., Calabretta, B., and Skorski, T. (1999). Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med. 189, 1229-1242.
95. Niwa, H., Burdon, T., Chambers, I., and Smith, A. (1998). Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 12, 2048-2060.
96. Nowell, P. C., and Hungerford, D. A. (1964). Chromosome changes in human leukemia and a tentative assessment of their significance. Ann. N. Y. Acad. Sci. 113, 654-662.
97. Oh, I. H., and Eaves, C. J. (2002). Overexpression of a dominant negative form of STAT3 selectively impairs hematopoietic stem cell activity. Oncogene 21, 4778-4787.
98. Oka, T., Ouchida, M., Koyama, M., Ogama, Y., Takada, S., Nakatani, Y., Tanaka, T., Yoshino, T., Hayashi, K., Ohara, N., Kondo, E., Takahashi, K., Tsuchiyama, J., Tanimoto, M., Shimizu, K., and Akagi, T. (2002). Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 62, 6390-6394.
99. Oka, T., Yoshino, T., Hayashi, K., Ohara, N., Nakanishi, T., Yamaai, Y., Hiraki, A., Sogawa, C. A., Kondo, E., Teramoto, N., Takahashi, K., Tsuchiyama, J., and Akagi, T. (2001). Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray. Am. J. Pathol. 159, 1495-1505.
100. Okabe, M., Kawamura, K., Miyagishima, T., Itaya, T., Goodwyn, D., Shoji, M., Vogler, W. R., Sakurada, K., Uehara, M., and Miyazaki, T. (1994a). Effect of herbimycin A, an inhibitor of tyrosine kinase, on protein tyrosine kinase activity and phosphotyrosyl proteins of Ph1-positive leukemia cells. Leuk. Res. 18, 213-220.
101. Okabe, M., Uehara, Y., Noshima, T., Itaya, T., Kunieda, Y., and Kurosawa, M. (1994b). In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk. Res. 18, 867-873.
102. Okabe, M., Uehara, Y., Miyagishima, T., Itaya, T., Tanaka, M., Kuni-Eda, Y., Kurosawa, M., and Miyazaki, T. (1992). Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth. Blood 80, 1330-1338.
103. Paget, S. (1889). The distribution of secondary growths in cancer of the breast. Lancet 133, 571-573.
104. Pene-Dumitrescu, T., and Smithgall, T. E. (2010). Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J. Biol. Chem. 285, 21446-21457.
105. Qu, C. K., Yu, W. M., Azzarelli, B., and Feng, G. S. (1999). Genetic evidence that Shp-2 tyrosine phosphatase is a signal enhancer of the epidermal growth factor receptor in mammals. Proc. Natl. Acad. Sci. U.S.A. 96, 8528-8533.
106. Quesnelle, K. M., Boehm, A. L., and Grandis, J. R. (2007). STAT-mediated EGFR signaling in cancer. J. Cell. Biochem. 102, 311-319.
107. Reddy, E. P., Korapati, A., Chaturvedi, P., and Rane, S. (2000). IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene 19, 2532-2547.
108. Reynaud, D., Pietras, E., Barry-Holson, K., Mir, A., Binnewies, M., Jeanne, M., Sala-Torra, O., Radich, J. P., and Passegue, E. (2011). IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 20, 661-673.
109. Seita, J., Asakawa, M., Ooehara, J., Takayanagi, S., Morita, Y., Watanabe, N., Fujita, K., Kudo, M., Mizuguchi, J., Ema, H., Nakauchi, H., and Yoshimoto, T. (2008). Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 111, 1903-1912.
110. Shain, K. H., Yarde, D. N., Meads, M. B., Huang, M., Jove, R., Hazlehurst, L. A., and Dalton, W. S. (2009). Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 69, 1009-1015.
111. Shuai, K. (2006). Regulation of cytokine signaling pathways by PIAS proteins. Cell Res. 16, 196-202.
112. Shuai, K., Horvath, C. M., Huang, L. H., Qureshi, S. A., Cowburn, D., and Darnell, J. E. Jr. (1994). Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76, 821-828.
113. Shuai, K., Stark, G. R., Kerr, I. M., and Darnell, J. E. Jr. (1993). A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 261, 1744-1746.
114. Sillaber, C., Gesbert, F., Frank, D. A., Sattler, M., and Griffin, J. D. (2000). STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 95, 2118-2125.
115. Sinibaldi, D., Wharton, W., Turkson, J., Bowman, T., Pledger, W. J., and Jove, R. (2000). Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 19, 5419-5427.
116. Spiekermann, K., Pau, M., Schwab, R., Schmieja, K., Franzrahe, S., and Hiddemann, W. (2002). Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp. Hematol. 30, 262-271.
117. Sumi, T., Fujimoto, Y., Nakatsuji, N., and Suemori, H. (2004). STAT3 is dispensable for maintenance of self-renewal in nonhuman primate embryonic stem cells. Stem Cells 22, 861-872.
118. Takeda, K., Clausen, B. E., Kaisho, T., Tsujimura, T., Terada, N., Forster, I., and Akira, S. (1999). Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39-49.
119. Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., and Akira, S. (1998). Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J. Immunol. 161, 4652-4660.
120. Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., Yoshida, N., Kishimoto, T., and Akira, S. (1997). Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. U.S.A. 94, 3801-3804.
121. Takizawa, M., Nobuhisa, I., Igarashi, K., Ueno, M., Nakashima, K., Kitamura, T., and Taga, T. (2003). Requirement of gp130 signaling for the AGM hematopoiesis. Exp. Hematol. 31, 283-289.
122. Talpaz, M., Kantarjian, H., Kurzrock, R., Trujillo, J. M., and Gutterman, J. U. (1991). Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann. Intern. Med. 114, 532-538.
123. Talpaz, M., Kantarjian, H. M., Mccredie, K., Trujillo, J. M., Keating, M. J., and Gutterman, J. U. (1986). Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N. Engl. J. Med. 314, 1065-1069.
124. Traer, E., Mackenzie, R., Snead, J., Agarwal, A., Eiring, A. M., O'Hare, T., Druker, B. J., and Deininger, M. W. (2011). Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia. doi:10.1038/leu.2011.325. [Epub ahead of print].
125. Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R. P., and Jove, R. (1998). Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 18, 2545-2552.
126. Wang, N., Li, Z., Ding, R., Frank, G. D., Senbonmatsu, T., Landon, E. J., Inagami, T., and Zhao, Z. J. (2006). Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling. J. Biol. Chem. 281, 21878-21883.
127. Weisberg, E., Manley, P. W., Breitenstein, W., Bruggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., Kung, A. L., Mestan, J., Daley, G. Q., Callahan, L., Catley, L., Cavazza, C., Azam, M., Neuberg, D., Wright, R. D., Gilliland, D. G., and Griffin, J. D. (2005). Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141.
128. Wen, Z., Zhong, Z., and Darnell, J. E. Jr. (1995). Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82, 241-250.
129. Wetzler, M., Brady, M. T., Tracy, E., Li, Z. R., Donohue, K. A., O'Loughlin, K. L., Cheng, Y., Mortazavi, A., Mcdonald, A. A., Kunapuli, P., Wallace, P. K., Baer, M. R., Cowell, J. K., and Baumann, H. (2006). Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin. Cancer Res. 12, 6817-6825.
130. Xu, D., and Qu, C. K. (2008). Protein tyrosine phosphatases in the JAK/STAT pathway. Front. Biosci. 13, 4925-4932.
131. Yamashina, K., Yamamoto, H., Chayama, K., Nakajima, K., and Kikuchi, A. (2006). Suppression of STAT3 activity by Duplin, which is a negative regulator of the Wnt signal. J. Biochem. 139, 305-314.
132. Yoshimura, A., Mori, H., Ohishi, M., Aki, D., and Hanada, T. (2003). Negative regulation of cytokine signaling influences inflammation. Curr. Opin. Immunol. 15, 704-708.
133. You, M., Yu, D. H., and Feng, G. S. (1999). Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol. Cell. Biol. 19, 2416-2424.
134. Zhang, T., Kee, W. H., Seow, K. T., Fung, W., and Cao, X. (2000). The coiled-coil domain of Stat3 is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6. Mol. Cell. Biol. 20, 7132-7139.
135. Zhang, X., Blenis, J., Li, H. C., Schindler, C., and Chen-Kiang, S. (1995). Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 267, 1990-1994.
136. Zhong, Z., Wen, Z., and Darnell, J. E. Jr. (1994). Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264, 95-98.
137. Zhu, J. F., Li, Z. J., Zhang, G. S., Meng, K., Kuang, W. Y., Li, J., Zhou, X. F., Li, R. J., Peng, H. L., Dai, C. W., Shen, J. K., Gong, F. J., Xu, Y. X., and Liu, S. F. (2011). Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3/AKT signalings. PLoS ONE 6, e23720. doi:10.1371/journal.pone.0023720